CSO Hedge Fund Litigation, No. 12-cv-7717 (GHW) (S.D.N.Y.) Southern District of New York Class: persons who purchased, held or otherwise acquired any class of shares in CSO Ltd. or CSO US Ltd. (two feeder funds in Citigroup’s Corporate Special Opportunities hedge fund) Attorneys: Frederic S. FoxFFox@kaplanfox.comJason A. Uris JUris@kaplanfox.com Kaplan Fox is court-appointed co-lead counsel for the plaintiffs in the class action against Citigroup, Inc. (“Citigroup”) and its wholly-owned subsidiary Citigroup Alternative Investments, LLC (collectively, “Defendants”) arising out of the collapse of Citigroup’s “Corporate Special Opportunities” or “CSO” hedge fund. The complaint alleges that Citigroup and CAI falsely represented their risk controls in the fund’s PPMs, and in 2007 fraudulently induced investors to refrain from redeeming with a series of false statements and omissions concerning the fund following an offer to purchase debt securities that exceeded the NAV of the fund. Citigroup booked a $62 million loss reserve with respect to the securities. On March 7, 2014, Judge Castel denied portions of Defendants’ motion to dismiss, finding that the facts led to a “strong inference” of fraud. On August 10, 2015, the parties reached an agreement to settle all claims for $13.5 million, and moved for an order preliminarily approving the settlement. The Court approved the settlement on August 19, 2015. If you purchased, held or otherwise acquired any class of shares in CSO Ltd. or CSO US Ltd., you might be a member of the Settlement Class and your rights might be affected by the Settlement. Please review the documents below for more information. Order dated March 7, 2014 Denying Defendants’ Motion to Dismiss in Part Settlement Agreement Memorandum of Law in Support of Motion for Preliminary Approval of Settlement Order Granting Preliminary Approval of Settlement Final Order and Judgment Order Approving Plan of Allocation Order Approving Attorneys’ Fees and Expenses Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Applied Therapeutics, Inc. See the Case Inari Medical, Inc. See the Case Barclays iPath Series B S&P 500 VIX Short-Term Futures ETN See the Case Charles River Laboratories International, Inc. See the Case Digital Currency Group, Inc. See the Case Spectrum Pharmaceuticals, Inc. See the Case Co-Diagnostics, Inc. See the Case Vale SA See the Case Geron Corporation See the Case Hecla Mining Company See the Case Textron Inc. See the Case Ambac Financial Group Securities Litigation See the Case
